Core Viewpoint - Saint Noble Pharmaceuticals-B (02257) experienced a significant increase in stock price, rising over 5% in the afternoon trading session, with a current price of 19.46 HKD and a trading volume of 32.44 million HKD [1] Group 1: Shareholding and Investment - Bloomage Biotechnology (Hong Kong) Limited and its affiliates have acquired 11.57 million shares of Saint Noble Pharmaceuticals, valued at approximately 139 million HKD [1] - Huaxi Biotechnology, through its wholly-owned subsidiary, subscribed to shares in Saint Noble Pharmaceuticals at a price of 12 HKD per share, totaling around 138 million HKD, resulting in a 9.44% ownership stake in the company [1] Group 2: Strategic Collaboration - Huaxi Biotechnology aims to leverage Saint Noble Pharmaceuticals' leading advantages in RNAi technology and PNP platform to explore the industrialization of small nucleic acid drugs in targeted fat reduction [1] - The focus will be on discussing clinical development and commercial cooperation for the STP705 targeted fat reduction project, accelerating the layout in the aesthetic medicine sector [1]